Praxis Precision Medicines (NASDAQ:PRAX) Issues Quarterly Earnings Results, Beats Estimates By $0.80 EPS

Praxis Precision Medicines (NASDAQ:PRAX) announced its quarterly earnings results on Thursday. The company reported ($2.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• Ulixacaltamide and relutrigine remain on track for potential FDA decisions, with target dates around January 2027 and December 27, 2026, respectively. Praxis said neither program is expected to require an advisory committee meeting, and FDA mid-cycle reviews identified no significant efficacy issues.
• Praxis has substantially advanced its commercial preparations, including hiring and training the relutrigine field team, building the ulixacaltamide sales force, establishing distribution and supply networks, and developing patient-support programs. Management expects to be launch-ready ahead of the anticipated approvals.
• Enrollment in the EMERALD broad developmental and epileptic encephalopathy study exceeded its target at approximately 200 patients across more than 50 genetic etiologies. If positive, the company expects the data could support a supplemental filing for relutrigine in 2027.
• Vormatrigine’s POWER1 study failed its primary endpoint in highly refractory focal-onset seizures, although it met a key responder secondary endpoint. Praxis plans to amend POWER2 and POWER3 based on learnings about dose, treatment duration, and patient selection, with both studies expected to restart by the fourth quarter.
• Second-quarter operating expenses increased to $96.9 million and operating cash usage rose to $78 million, reflecting greater development and commercial spending. Praxis ended the quarter with $1.4 billion in cash and marketable securities, which management believes funds operations into 2028.

Praxis Precision Medicines Stock Performance

Shares of NASDAQ PRAX traded down $9.40 during midday trading on Friday, hitting $360.76. 454,827 shares of the company’s stock traded hands, compared to its average volume of 476,464. The firm has a fifty day moving average of $303.77 and a 200 day moving average of $315.47. Praxis Precision Medicines has a 1 year low of $37.19 and a 1 year high of $382.54. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of -26.98 and a beta of 2.78.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PRAX. Oppenheimer reaffirmed an “outperform” rating and set a $650.00 price target (down from $750.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. HC Wainwright lowered their price objective on shares of Praxis Precision Medicines from $1,245.00 to $1,201.00 and set a “buy” rating on the stock in a research report on Tuesday, June 2nd. Needham & Company LLC raised their target price on shares of Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a “buy” rating in a report on Thursday. Truist Financial set a $616.00 target price on shares of Praxis Precision Medicines and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research note on Wednesday, May 27th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of “Buy” and a consensus target price of $573.05.

Insider Activity

In related news, Director Jill Desimone sold 11,600 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the completion of the sale, the director directly owned 2,337 shares in the company, valued at approximately $727,554.84. The trade was a 83.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PRAX. Amundi bought a new position in Praxis Precision Medicines in the 4th quarter worth $233,000. MML Investors Services LLC bought a new position in shares of Praxis Precision Medicines in the fourth quarter worth about $255,000. Ieq Capital LLC purchased a new stake in Praxis Precision Medicines in the 4th quarter worth approximately $240,000. EntryPoint Capital LLC bought a new stake in Praxis Precision Medicines during the 4th quarter worth approximately $261,000. Finally, Russell Investments Group Ltd. raised its stake in Praxis Precision Medicines by 1,668.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,404 shares of the company’s stock worth $233,000 after acquiring an additional 4,155 shares during the period. Hedge funds and other institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.